Finalized study design and protocol mark major milestone to investigate natural Psilocybin VANCOUVER, BC, Oct. 20, 2021 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to have finalized the study design and protocol for a Phase 1 clinical trial on a naturally derived Psilocybin extract…


Previous articleatai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change
Next articleTryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders